More than 23.5 million Americans (>7% of the population) are the existing or emerging consumers of drugs targeting autoimmune diseases alone not including immune-dependent malignancies, and the prevalence is rising. The global autoimmune disease therapeutics market size alone can exceed $125 billion by the year 2025. Similarly, immune dependent cancer market size can exceed $130 by 2030. Interleukin receptor-associated kinase 4 (IRAK4) orchestrates many chronic inflammatory diseases and high-risk solid and hematopoietic malignancies and is the prime target of pharmaceutical industries currently to develop high-commercial value new drug products.
Rochester researchers have developed a novel, selective and very-target specific IRAK4 inhibitor, which 1) Inhibits IRAK4 and it is specific to IRAK4 only; 2) has minimum off-target effects; 3) can be used in oral therapy and 4) has a short path of synthesis and no optical isomer challenges (unlike Pfizer’s PF0665833).
Targeting IRAK4 via this inhibitor can:
- Enhance therapy for hematologic malignancies by targeting a cell-autonomous cancer cell dependency;
- Improve marrow function via targeting the bone marrow microenvironment;
- Block solid tumor microenvironment supported malignancies;
- Be used in oral therapy;
- Can potentially become a therapeutic agent for chemoresistant cancers.
- Immune disorders
- Rheumatoid arthritis
- Type-1 diabetes
- Multiple sclerosis
- Pancreatic cancer
- Colitis induced tumorigenesis
- Hematologic malignancies and chemoresistance in colorectal cancer
Seeking to license the technology exclusively in multiple fields of use.
- PCT application pending
- Patent application submitted
TTO Home Page: http://rochester.technologypublisher.com
Name: Scott Catlin
Title: Vice President, Corporate Counsel